TOKYO, May 07 (Pulse News Wire) – RaQualia Pharma Inc. (4579.T) announced positive results from the phase III clinical trial of its gastric acid secretion inhibitor, tegoprazan, presented at Digestive Disease Week (DDW) 2026.
The TRIUMpH-EE study demonstrated statistical superiority of tegoprazan over comparator drug lansoprazole in healing and maintaining remission of erosive esophagitis across all severity levels, particularly in severe cases (LA Grade C/D). In the acute healing phase, tegoprazan showed higher complete healing rates compared to lansoprazole, achieving statistical significance at both two weeks and eight weeks. During the maintenance phase, tegoprazan maintained superior healing outcomes up to 24 weeks, especially among patients with severe erosive esophagitis.
Additionally, tegoprazan improved heartburn-free days more effectively than lansoprazole, showing statistical superiority in severe cases. Safety profiles remained consistent throughout the trials, with adverse events comparable to those seen with lansoprazole. Alan Cooke, CEO of Sebela Pharmaceuticals, highlighted the potential of tegoprazan to offer faster and more sustained relief for GERD patients, including those who respond inadequately to traditional PPI treatments.
🟡 Confidence: Standard AI-translated content.